NCT00621179

Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF

Do Endometrial Implantation Markers Predict in Vitro Fertilization-embryo Transfer Cycle Outcomes in Endometriosis Patients Pretreated With Leuprolide Acetate in Depot Suspension?

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Colorado Center for Reproductive Medicine · Academic / Other
• Sex: Female
• Age: 21 Years – 42 Years
• Healthy volunteers: Not accepted

Summary

This prospective randomized trial evaluates whether one can predict which infertile women with endometriosis who are candidates for in vitro fertilization will benefit from prolonged therapy with a GnRH agonist by the determination of the absence of endometrial expression of the integrin, alpha v, beta 3 vitronectin. This is a prospective randomized trial in which all patients will undergo endometrial biopsy prior to initiation of ovarian stimulation for in vitro fertilization and then undergo randomization to a three month course of a depot preparation of the GnRH agonist leuprolide acetate in depot suspension prior to ovarian stimulation or standard therapy. prio

Detailed description

See summary

Conditions

• Endometriosis
• Infertility

Interventions

Type	Name	Description
DRUG	Leuprolide acetate in depot suspension	Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3
OTHER	No intervention

Timeline

• Start date: 2003-03-01
• Primary completion: 2009-08-01
• Completion: 2010-01-01
• First posted: 2008-02-22
• Last updated: 2021-08-10
• Results posted: 2020-10-05

Locations

1 site across 1 country: United States